Emerging Therapeutics to boom AL Amyloidosis Treatment Synopsis

02 Mar 2021
www.globenewswire.com
AntibodyOrphan DrugVaccineSmall molecular drugADC
Los Angeles, March 01, 2021 (GLOBE NEWSWIRE) -- Emerging Therapeutics to boom AL Amyloidosis Treatment Synopsis Advances in the AL Amyloidosis clinical trials promote treatment as 15+ companies are working towards the development of novel approaches. DelveInsight’s “Amyloid light-chain Amyloidosis (AL) Pipeline Insight'' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Amyloid light-chain Amyloidosis pipeline landscapes. It comprises AL Amyloidosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Amyloid light-chain Amyloidosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive AL Amyloidosis pipeline products. Some of the important features of the AL Amyloidosis Pipeline Report The companies such as Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and several others are working on novel approaches for AL Amyloidosis treatment. and several others are working on novel approaches for AL Amyloidosis treatment. In January 2019, Alexion Pharmaceuticals and Caelum Biosciences declared a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. declared a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 has secured Orphan Drug Designation from both the US Food and Drug Administration (FDA) and European Medicine Agency as a therapy for AL amyloidosis patients. has secured Orphan Drug Designation from both the US Food and Drug Administration (FDA) and European Medicine Agency as a therapy for AL amyloidosis patients. In May 2020, Sorrento Therapeutics announced it had received clearance from the FDA for its investigational new drug (IND) application for STI-6129. Request for sample pages @ Amyloid light-chain Amyloidosis Pipeline Insight Report Amyloid Light-chain Amyloidosis (AL) is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. It is caused by a bone marrow disorder. AL amyloidosis diagnosis requires demonstration of amyloid in tissue and demonstration of a plasma cell dyscrasia. The current therapeutic approach to systemic amyloidosis is based on the observations that organ dysfunction enhances and survival increases if the synthesis of the amyloidogenic protein precursor is stopped. The AL amyloidosis therapy aims to rapidly reduce the supply of amyloidogenic monoclonal light chains by repressing the underlying plasma cell dyscrasia. AL Amyloidosis Emerging Drugs CAEL-101 by Caelum Biosciences CAEL-101 is a fibril-reactive monoclonal antibody (mAb) that is currently in phase III clinical development for the treatment of amyloid light-chain (AL) amyloidosis patients. Bendamustine by Astellas Pharma GmbH Astellas Pharma GmbH is developing bendamustine for the AL amyloidosis treatment. It is currently in the phase II stage of development. STI-6129 by Sorrento Therapeutics STI-6129, a CD38-targeting antibody-drug conjugate (ADC) that is being developed by Sorrento Therapeutics to treat Amyloid light-chain Amyloidosis. It is currently in the phase I stage of development. For further product profiles, request @ Amyloid light-chain Amyloidosis Pipeline Insight Report Scope of AL Amyloidosis Pipeline Drug Insight Coverage: Global Global Major Players: 15+ Key Players Prominent Players: Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and many others. Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and many others. Key Drugs Profiles: 15+ Pro ducts Phases: Amyloid Light-chain Amyloidosis Late-stage (Phase III) AL Amyloidosis Therapies (Phase II) Amyloid Light-chain Amyloidosis Therapies (Phase I) AL Amyloidosis Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Molecule Types: Gene therapies Small molecule Vaccines Polymers Peptides Monoclonal antibodies Mechanism of Action: Protease inhibitors Immunomodulatory Multiple kinase inhibitor Route of Administration: Infusion Intradermal Intramuscular Intranasal Intravaginal Oral Parenteral Subcutaneous Topical Product Types: Monotherapy Combination  Combination Key Questions regarding Current AL Amyloidosis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Amyloid light-chain Amyloidosis treatment? How many companies are developing therapies for the treatment of AL Amyloidosis? How many are Amyloid light-chain Amyloidosis emerging therapies in the early-stage, mid-stage, and late stages of development for the treatment of AL Amyloidosis? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Amyloid light-chain Amyloidosis market? Which are the dormant and discontinued products and the reasons for the same? What is the unmet need for current therapies for the treatment of AL Amyloidosis? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Amyloid light-chain Amyloidosis therapies? What are the critical designations that have been granted for the emerging therapies for AL Amyloidosis? How many patents are granted and pending for the emerging therapies to treat Amyloid light-chain Amyloidosis? Table of Contents Get customized pipeline report @ AL Amyloidosis Drug Treatment Related Reports DelveInsight’s AL Amyloidosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. DelveInsight's AL Amyloidosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of AL Amyloidosis. DelveInsight's Hereditary ATTR (hATTR) amyloidosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. DelveInsight's "Hereditary Transthyretin Amyloidosis (hATTR) amyloidosis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. DelveInsight's Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight' s Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology. DelveInsight's Palmar Hyperhidrosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.